MacroGenics
✓ Verified ManufacturerAbout
MacroGenics represents a leading biopharmaceutical company based in Rockville, Maryland, specializing in the development and manufacturing of innovative monoclonal antibody-based therapeutics for cancer treatment. The company operates as a fully-integrated organization with comprehensive antibody development capabilities, including GMP manufacturing facilities that ensure the highest quality standards for therapeutic production. The pharmaceutical manufacturer focuses on developing breakthrough biologics and life-changing medicines for patients with unmet medical needs, particularly in oncology. MacroGenics maintains an extensive pipeline of investigational product candidates, including Lorigerlimab, MGC026, MGC028, and MGD024, each targeting different cancer pathways through advanced antibody technologies. MacroGenics leverages sophisticated technology platforms including monoclonal antibody development and Antibody-Drug Conjugate technologies to create targeted cancer therapies. The company also provides Contract Development and Manufacturing Organization services, offering pharmaceutical development and manufacturing solutions to external partners. With state-of-the-art facilities in Maryland, MacroGenics combines research excellence with manufacturing expertise to advance innovative cancer treatments from laboratory concept through clinical development. The company maintains rigorous quality standards throughout its pharmaceutical manufacturing processes, ensuring compliance with FDA regulations and industry best practices. MacroGenics continues to expand its therapeutic portfolio while maintaining its commitment to developing transformative medicines that address critical healthcare challenges in oncology.